RTTNews | Jul 7, 2021 09:53AM EDT

09:53 Wednesday, July 7, 2021 (RTTNews.com) - Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) jumped over 10% on Wednesday morning after the company reported its migraine drug generated $93 million in sales.

BHVN is currently trading at $109.33, up $10.49 or 10.61%, on the NYSE. In the past 3-month period, the stock has gained over 60%.

Based on preliminary results, the company reported $93 million in net product revenue from sales of Nurtec ODT, its drug to treat migraine in adults, in the second quarter. Total prescriptions of Nurtec ODT from product launch to as of June 30, 2021 were over 750,000, with approximately 38,000 unique prescribers.

Commenting on the drug's performance, CEO Vlad Coric said, "We are thrilled to report preliminary net product revenue of $93 million for NURTEC ODT in the second quarter that continues to exceed expectations and demonstrates the impact that NURTEC ODT is having on patients with migraine."

Read the original article on RTTNews ( https://www.rttnews.com/3207526/biohaven-pharmaceutical-jumps-10-after-migraine-drug-generates-93-mln-in-q2-sales.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved